Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
NCT07046494
Recruiting
This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania associated with bipolar I disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/21/2025
Locations: Woodland International Research Group, Little Rock, Arkansas +10 locations
Conditions: Bipolar 1 Disorder
Register for Updates
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will evaluate how safe and effective risankizumab is compared to vedolizumab in treating adult participants with moderate to severe UC who are naive to targeted therapies (TaTs). Risankizumab and vedolizumab are approved medications for moderate to severe UC in multiple countries. Participants who meet the eligibility criteria... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/21/2025
Locations: Digestive Health Specialists /ID# 274785, Dothan, Alabama +93 locations
Conditions: Ulcerative Colitis
Register for Updates
Avexitide for Treatment of Post-Bariatric Hypoglycemia
NCT06747468
Recruiting
AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess avexitide compared to placebo for safety and efficacy, measured by reduction of hypoglycemic events. The study includes a Screening period with a Run-in period (of up to 6- and 3-weeks, respectively); a randomized, double-blind, placebo-controlled study treatment period of 16 weeks; and a two-part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: Stanford Health Care - Endocrinology Clinic, Stanford, California +20 locations
Conditions: Post Bariatric Hypoglycemia
Register for Updates
Influence of Melatonin on Cardiovascular and Thermoregulatory Responses to Stress
NCT07138443
Recruiting
This study aims to evaluate the influence of acute oral melatonin supplementation on cardiovascular and skin temperature responses to mental stress. The hypothesis is that acute melatonin will lead to reduced cardiovascular and skin temperature responsiveness to acute mental stress.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/21/2025
Locations: Baylor University Autonomic Function Laboratory, Waco, Texas
Conditions: Stress, Mental Stress
Register for Updates
Stone and Laser Therapies Post-Market Study (SALT)
NCT06982235
Recruiting
The objective of the SALT Study is to obtain post-market safety and device performance data for Boston Scientific's Stone and BPH study devices used during a diagnostic and/or therapeutic urinary tract procedure (e.g., transurethral or percutaneous access routes) or benign prostatic hyperplasia (BPH) treatment.
Gender:
ALL
Ages:
All
Trial Updated:
08/21/2025
Locations: University of Miami Hospital, Miami, Florida
Conditions: Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary, Urinary Tract Procedure
Register for Updates
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
NCT06792500
Recruiting
This is a parallel arm non-randomized dose-escalation, open-label basket exploratory phase 1 clinical trial where Mitochondrial encephalopathy, lactic acidosis, stroke-like episodes (MELAS) and Leber's hereditary optic neuropathy-Plus (LHON-Plus) participants will undergo simultaneous enrollment in two disease-based arms and receive daily oral doses of glycerol tributyrate to assess its safety and potential for efficacy using clinical, biochemical, and molecular evidence. This study will utiliz... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/21/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Register for Updates
Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults
NCT07095231
Recruiting
This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of STX-S in adults who have previously received a primary series and at least one booster with an authorized or licensed SARS-CoV-2 parenteral vaccine. The study is designed as a non-randomized, open-label, dose-escalation clinical trial evaluating three dose levels of STX-S. A sample size of 60 participants (20 participants per dose cohort) is anticipated. The primary objective is to evaluate the safety and... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
08/21/2025
Locations: University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York +2 locations
Conditions: COVID-19
Register for Updates
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494
Recruiting
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein tha... Read More
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
08/21/2025
Locations: JEM Research Institute ( Site 1046), Atlantis, Florida +2 locations
Conditions: Early Alzheimer's Disease
Register for Updates
Long-Covid-19 Alleviation Through Learning Mindfulness Study
NCT07140094
Recruiting
This research is being done to study a mindfulness intervention among people who have symptoms of Post-Acute Sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Mindfulness is defined as paying attention to the present moment with non-judgment and acceptance. Here the investigators are studying whether a mindfulness intervention can help reduce stress, reduce Long COVID symptoms, and improve quality of life among people living with Long COVID. The mindfulness intervention is a ser... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: Columbia University, New York, New York
Conditions: Long COVID, Long Covid19, Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 Infection, COVID Long-Haul
Register for Updates
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)
NCT06911502
Recruiting
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: Local Institution - 0225, Birmingham, Alabama +153 locations
Conditions: Follicular Lymphoma
Register for Updates
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310
Recruiting
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: Local Institution - 0347, Birmingham, Alabama +328 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
NCT06747572
Recruiting
The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
08/21/2025
Locations: Alabama Kidney Research, Alabaster, Alabama +39 locations
Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Register for Updates